HIV/AIDS in Sub-Saharan Africa
How HIV/AIDS affects 48 countries in Sub-Saharan Africa.
| # | Country | Share (%) |
|---|
HIV/AIDS has claimed over 40 million lives since the epidemic began in the early 1980s. Human Immunodeficiency Virus destroys CD4+ T-cells, progressively weakening the immune system until opportunistic infections and cancers become lethal — the stage known as AIDS. Sub-Saharan Africa remains the epicentre, home to approximately two-thirds of all people living with HIV. Southern Africa bears the heaviest burden, with countries like Eswatini and Lesotho recording adult prevalence rates above 20%. Combination antiretroviral therapy (ART), available since 1996, has transformed HIV into a manageable chronic condition for those with access. Annual AIDS-related deaths have declined from a peak of approximately 1.9 million in 2004 to under 650,000 by 2022. However, 1.3 million new infections still occur each year, with key populations — men who have sex with men, people who inject drugs, sex workers, and transgender people — disproportionately affected. Treatment coverage gaps persist in West and Central Africa, Eastern Europe, and Central Asia, where stigma, criminalisation, and health system weaknesses impede progress toward the UNAIDS 95-95-95 targets. Sub-Saharan Africa faces the world's most acute health challenges, with the youngest population of any region, the highest burden of infectious diseases, and health systems constrained by limited financing and workforce shortages. In Sub-Saharan Africa, hiv/aids mortality is broadly in line with global averages, though the region's young demographic profile and high infectious disease burden shape the overall mortality landscape.
HIV prevention combines biomedical, behavioural, and structural approaches. Pre-exposure prophylaxis (PrEP) reduces acquisition risk by over 90%. Condom use, voluntary male circumcision, harm reduction for people who inject drugs, and elimination of mother-to-child transmission are all proven strategies. Treatment as prevention (U=U: undetectable equals untransmittable) means that people on effective ART cannot sexually transmit the virus. Achieving the 95-95-95 targets — 95% diagnosed, 95% on treatment, 95% virally suppressed — would effectively end AIDS as a public health threat.
The mortality estimates presented on this page are derived from the Global Burden of Disease (GBD) study, produced by the Institute for Health Metrics and Evaluation (IHME). The GBD synthesizes data from vital registration systems, verbal autopsies, cancer registries, and surveillance networks across more than 200 countries and territories. Death rates are expressed per 100,000 population and are age-standardized, which adjusts for differences in age structure between populations so that comparisons across countries and over time reflect genuine differences in mortality risk rather than demographic composition.
The dataset typically covers the period from 1990 to 2023, although availability varies by country and cause. When interpreting the figures for hiv/aids in Sub-Saharan Africa, note that higher age-standardized rates indicate a greater mortality burden independent of whether a country's population is older or younger. Trends over time reveal whether public health interventions, economic development, and health system improvements have reduced or increased the toll of this condition in the region.
The cause-of-death categories used on this page follow the Global Burden of Disease cause hierarchy, a standardized classification that groups individual ICD-coded causes into clinically meaningful categories. The "share of deaths" metric shows what percentage of all deaths in a given country or region are attributed to hiv/aids. A rising share does not necessarily mean more people are dying from this cause — it may reflect success in reducing competing causes of death. Always examine both absolute rates and shares for a complete picture of mortality patterns in Sub-Saharan Africa.